184 related articles for article (PubMed ID: 6791210)
1. Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction.
Pickar D; Cohen RM; Jimerson DC; Lake CR; Murphy DL
Psychopharmacology (Berl); 1981; 74(1):8-12. PubMed ID: 6791210
[TBL] [Abstract][Full Text] [Related]
2. Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.
Pickar D; Cohen RM; Jimerson DC; Murphy DL
Psychopharmacology (Berl); 1981; 74(1):4-7. PubMed ID: 6791202
[TBL] [Abstract][Full Text] [Related]
3. Tyramine pressor sensitivity changes during deprenyl treatment.
Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
[TBL] [Abstract][Full Text] [Related]
4. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
Murphy DL; Lipper S; Slater S; Shiling D
Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
[TBL] [Abstract][Full Text] [Related]
7. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
Murphy DL; Karoum F; Pickar D; Cohen RM; Lipper S; Mellow AM; Tariot PN; Sunderland T
J Neural Transm Suppl; 1998; 52():39-48. PubMed ID: 9564606
[TBL] [Abstract][Full Text] [Related]
8. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
Kerecsen L; Bunag RD
J Pharmacol Exp Ther; 1989 Nov; 251(2):645-9. PubMed ID: 2509682
[TBL] [Abstract][Full Text] [Related]
9. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
[TBL] [Abstract][Full Text] [Related]
10. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB
Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669
[TBL] [Abstract][Full Text] [Related]
11. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
Abdo-Rubo A
Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
Lenzen S; Nahrstedt H; Panten U
Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
[TBL] [Abstract][Full Text] [Related]
15. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.
Finberg JP; Youdim MB
Br J Pharmacol; 1985 Jun; 85(2):541-6. PubMed ID: 3928010
[TBL] [Abstract][Full Text] [Related]
16. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.
Finberg JP; Tenne M
Br J Pharmacol; 1982 Sep; 77(1):13-21. PubMed ID: 6127132
[TBL] [Abstract][Full Text] [Related]
17. Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.
Prasad A; Glover V; Goodwin BL; Sandler M; Signy M; Smith SE
Psychopharmacology (Berl); 1988; 95(4):540-3. PubMed ID: 3145523
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
Humphrey SJ; Curry JT; Turman CN; Stryd RP
J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase (MAO)-A but not MAO-B inhibitors potentiate tyramine-induced catecholamine release from PC12 cells.
Youdim MB
J Neurochem; 1990 Feb; 54(2):411-4. PubMed ID: 2299343
[TBL] [Abstract][Full Text] [Related]
20. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
Gal S; Abassi ZA; Youdim MB
Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
